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ABSTRACT
Lysyl Oxidase-like 2 (LOXL2), a member of the lysyl oxidase family of amine 
oxidases is known to be important in normal tissue development and homeostasis, 
as well as the onset and progression of solid tumors. Here we tested the anti-tumor 
properties of two generations of novel small molecule LOXL2 inhibitor in the MDA-
MB-231 human model of breast cancer. We confirmed a functional role for LOXL2 activity 
in the progression of primary breast cancer. Inhibition of LOXL2 activity inhibited the 
growth of primary tumors and reduced primary tumor angiogenesis. Dual inhibition 
of LOXL2 and LOX showed a greater effect and also led to a lower overall metastatic 
burden in the lung and liver. Our data provides the first evidence to support a role for 
LOXL2 specific small molecule inhibitors as a potential therapy in breast cancer.
INTRODUCTION
Solid tumors remain one of the biggest burdens 
of disease in the developed world. At present, surgery 
remains the gold standard for treating patients with 
resectable disease. Furthermore, early detection is seen 
as one of the most effective approaches for improving 
patient survival. Thus, the ability to treat and contain 
primary tumors carries with it the ability to enhance 
surgical outcome. There is mounting evidence that 
changes in the extracellular matrix (ECM) are critical in 
promoting the growth and metastatic dissemination of 
solid tumors[1]. Furthermore, many of the biochemical 
and biomechanical changes in the tumor ECM are a direct 
result of tumor action [2]. Of late, particular focus has 
been on the role of matrix remodeling enzymes, and their 
function in promoting tumor progression [3]. As such, 
enzymes that post-translationally modify the ECM, and 
in particular those that cross-link the ECM, such as the 
lysyl oxidase family are of particular interest as targetable 
molecules [4].
The lysyl oxidase family of secreted enzymes has 
garnered much attention over recent years. Consisting of 
Lysyl oxidase (LOX) and 4 LOX-like enzymes (LOXL1 
to 4), this is a family of secreted, copper dependent amine 
oxidases, which predominantly catalyze the cross-linking 
of ECM proteins, including collagens and elastin. All of 
the family members possess a conserved catalytic domain 
yet exhibit divergent N-termini, which is thought to confer 
context specific functions. Despite the overlap in sequence 
homology, there appears to be little reported redundancy 
in biological function between family members. Yet, 
several recent papers in the field have implicated many 
of these family members as potential therapeutic targets, 
none-less-so than LOXL2. LOXL2 is an 87kDa secreted 
protein that has been implicated in the progression of solid 
tumors including breast, pancreatic, biliary, esophageal, 
prostate, head and neck, colon and gastric cancers [5–12]. 
Our objective was to evaluate the efficacy of two 
generations of novel LOXL2 inhibitor in both in vitro and 
in vivo models of human breast cancer in order to determine 
the functional role of LOXL2 in breast cancer progression. 
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RESULTS
The PXS compounds as a new generation of 
LOXL2 inhibitors
β-aminopropionitrile (BAPN) has long served as 
the archetypal lysyl oxidase inhibitor, however variable 
potency, and therefore selectivity, has often been 
reported. Indeed BAPN, whilst originally proposed to 
specifically inhibit LOX activity, has also been shown 
to inhibit LOXL2 activity with a similar potency. This 
promiscuity, coupled with the lack of amenable sites for 
chemical modification, has rendered BAPN of little use for 
clinical drug development and detailed investigations into 
dissecting the differences in the functional role of LOX 
and/or LOXL2 in diseases such as cancer and fibrosis. 
Derivation of an alternative (haloallylamine-based) 
inhibitor scaffold has now led to the development of new 
compounds [13, 14] with different selectivity profiles 
to facilitate such investigations. These compounds are 
mechanism-based inhibitors with drug-like properties. 
PXS-S1A is a first generation inhibitor that displays 
almost identical activity and selectivity (relative to BAPN) 
when tested against recombinant LOXL2 enzyme (pIC50 ± 
SD, n: PXS-S1A 6.8 ± 0.2; 111; BAPN 6.4 ± 0.1; 45) 
(Figure 1A) and comparable activity and selectivity (relative 
to BAPN) to native human LOX enzyme (Figure 1B) 
(PXS-S1A 5.3 ± 0.3, 3; BAPN pIC50 ± SD, n: 5.5 ± 0.1, 
8). Given the similarity in affinities for LOX and LOXL2, 
PXS-S1A represents an incredibly versatile and powerful 
dual inhibitor of both enzymes. The crucial difference 
between PXS-S1A and BAPN, however, is the chemical 
tractability of the former species, meaning that structural 
modifications can easily be made to improve LOXL2 
potency and/or decrease LOX potency, thereby leading to 
significant increases in selectivity. Such modifications led 
to the discovery and generation of PXS-S2A, a potent and 
highly selective LOXL2 inhibitor (pIC50 ± SD, n: 8.3 ± 0.1, 
49) (Figure 1C) with comparable LOX activity to PXS-S1A 
(pIC50 ± SD, n: 5.9 ± 0.1, 13) (Figure 1D). PXS-S2A does 
not show any auxiliary pharmacology in standard profiling 
assays (SafetyScreen 87; Eurofins Panlabs Inc.). It shows 
excellent in vitro properties (high plasma stability and low 
plasma protein binding) as well as high metabolic stability. 
The orally bioavailable form of PXS-S2A; PXS-S2B; is 
readily absorbed following oral gavage, distributes well 
into tissues and forms PXS-S2A. Safety testing showed that 
PXS-S2B dosed daily at 10mg/kg over 24 weeks in healthy 
mice led to no detectable clinical signs.
In terms of selectivity over other related human 
amine oxidases (semicarbazide-sensitive amine oxidase 
(SSAO), diamine oxidase (DAO), monoamine oxidase 
(MAO-A) and (MAO-B)), PXS-S1A exhibited greater 
than 50 fold and PXS-S2A greater than 500 fold higher 
selectivity (Table 1). Whilst mechanism-based amine 
oxidase inhibitors have been reported to potentially serve 
as substrates for some amine oxidases [15], there was no 
significant (> 20%) increase of AMPLEX Red signal over 
baseline for high concentrations (> 30 µM) of PXS-S1A for 
LOXL2 or MAO-B, although > 20% increases occurred for 
SSAO and DAO. In contrast to this, PXS-S2A did not show 
any significant activity against any enzyme tested even at 
high concentrations (LOXL2, DAO, MAO-B, SSAO).
In light of the numerous reports with regard to the 
critical and differential roles of LOX and LOXL2 in solid 
tumor progression, in particular breast cancer [3, 4], the 
availability of a dual LOX/LOXL2 inhibitor (PXS-S1A) 
and highly specific LOXL2 inhibitor (PXS-S2A), lays the 
foundation for dissecting the specific functional role of 
LOXL2 in breast cancer. It also allows the evaluation of 
the potential of small molecule targeting of LOXL2 as a 
therapeutic approach in breast cancer.
PXS compounds inhibit proliferation, migration 
and invasion in vitro
The efficacy of the LOXL2 inhibitors was tested 
in vitro in proliferation, migration and invasion assays in the 
MDA-MB-231 triple negative human breast cancer model. 
These cells express high levels of LOXL2 and moderate 
levels of LOX, with little or no expression of other LOXL 
family members (LOXL1, 3 or 4) (Supplementary Figure 
1A) [7, 16]. In 2-dimensional proliferation assays on 
plastic (measured as in change confluence over time with 
increasing drug concentration), both inhibitors showed dose 
dependent inhibition of breast cancer cell proliferation over 
96 hours, with PXS-S1A exhibiting a greater effect against 
2D proliferation than PXS-S2A (Figure 2A). This inhibition 
of proliferation was also observed in 3-dimensional 
proliferation assays in 3D collagen I matrices (as measured 
by MTS assay). Both the dual inhibitor PXS-S1A and the 
LOXL2 specific PXS-S2A inhibited cellular proliferation in 
dose dependent manners measured over 8 days (Figure 2B). 
Our data show that both LOX and LOXL2 play a significant 
role in 2D and 3D proliferation of breast cancer cells.
In 2-dimensional wound closure (migration) assays 
on plastic (Figure 2C), the dual inhibitor PXS-S1A 
significantly affected 2D wound closure in a dose 
dependent manner, whereas PXS-S2A only showed 
a reduced, albeit still significant effect, at higher 
concentrations, suggesting that again, both LOX and 
LOXL2 are important for 2D migration (Figure 2D and 
Supplementary Figure 1B). Importantly, we observe that 
this effect is not as a result of induction of apoptosis 
(Supplementary Figure 1C) as no differences in apoptosis 
were observed between inhibitor treated and vehicle 
control. In 3-dimentional spheroid based invasion assays, 
both the dual inhibitor PXS-S1A and the LOXL2 selective 
PXS-S2A inhibited 3D invasion into the surrounding 
collagen I matrix (Figure 2E and 2F).
To confirm the effects of small molecule mediated 
LOXL2 inhibition in breast cancer cells, we stably 
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knocked down LOXL2 in the MDA-MB-231 cells using 
separate shRNA constructs. This led to a significant 
and stable reduction in the levels of LOXL2 mRNA 
and secreted protein in 2 hairpins (shLOXL2 #1 and 
shLOXL2 #5) (Figure 3A and 3B). Thus, both of these 
hairpins (#1 and #5) were used for subsequent validation 
studies. We also confirmed that stable LOXL2 knockdown 
did not alter the expression patterns (where detectable) of 
the other family members (LOX, LOXL1, LOXL3 and 
LOXL4) (Supplementary Figure 2A). In 2D growth assays 
on plastic, shLOXL2 cells showed a small and significant 
difference in proliferation rates (Figure 3C) at day 3 and 4 
in line with data shown in Figure 2. In addition to this, in 
both 3D growth assays and 3D invasion assays in collagen 
I matrices, shLOXL2 cells showed lower proliferation 
rates and invasive capabilities when compared to 
scrambled control cells (Figure 3D and 3E) confirming 
the effects seen with the LOXL2 specific PXS-S2A on 
proliferation and invasion of breast cancer cells. Thus, our 
data show that genetic silencing of LOXL2 mimics the 
effects of the LOXL2 specific inhibitor, PXS-S2A in vitro. 
Targeting LOXL2 in vivo delays tumor growth 
and reduces tumor burden
We next tested the efficacy of both generations 
of inhibitors in vivo. MDA-MB-231 human breast 
cancer cells were orthotopically implanted into the 
4th mammary fatpad of athymic Nude (NCR) mice. 
Once the tumors became palpable, typically measuring 
10 mm3, and appearing within 7–10 days of implant, 
treatment with the PXS LOXL2 small molecule 
inhibitors (PXS-S1A and PXS-S2B [PXS-S2B being 
the pro-drug version of PXS-S2A used in vitro]) 
commenced. Both generations of inhibitor (PXS-S1A 
and PXS-S2B) showed clear inhibitory effects on 
primary tumor growth one week after treatment 
commenced which continued showing significance 
at approximately 2–3 weeks post treatment start 
(Figure 4A and 4B). At experimental endpoints, PXS-S1A 
showed a ~75% decrease in primary tumor volume with 
PXS-S2B showing an ~55% decrease in tumor volume 
(Figure 4A and 4B). Our data indicate that the specific 
inhibition of LOXL2 alone will delay primary tumor 
growth, suggesting a LOXL2 specific role in primary 
tumor growth. Dual LOX / LOXL2 inhibition (PXS-S1A) 
showed a greater degree of inhibition supporting previous 
studies on the role of LOX in breast cancer primary tumor 
growth. Our data support the use of both approaches as a 
potential therapeutic intervention for breast cancer.
To confirm whether the observed effects were as 
a result of targeting primary tumor secreted rather than 
stromal-secreted LOX and LOXL2, we utilized our two 
shLOXL2 MDA-MB-231 cell lines described above. 
Scrambled control (shControl) and shLOXL2 lines 
were implanted orthotopically into the 4th mammary 
fatpad as described above. Stable knockdown of LOXL2 
significantly inhibited the growth of primary tumors in 
the two separate shRNA constructs (Figure 4C). Together 
these data further support that the targeting of LOXL2 
secreted from primary tumor cells is capable of delaying 
the growth of primary breast tumors in vivo.
Figure 1: The PXS compounds as a new generation of LOXL2 inhibitors. (A) pIC50 plots for PXS-S1A and BAPN against 
recombinant LOXL2 protein and (B) native human LOX enzyme showing a very similar activity and selectivity profile (C) pIC50 plots for 
the modified second generation PXS-S2A and BAPN against recombinant LOXL2 protein and (D) native human LOX enzyme showing 
significantly enhanced LOXL2 selectivity.
Table 1: pIC50 (M) selectivity for PXS-S1A and PXS-S2A against LOXL2, and other related human 
amine oxidases (semicarbazide-sensitive amine oxidase (SSAO), diamine oxidase (DAO), and 
monoamine oxidases (MAO-A) and (MAO-B))
Lysyl Oxidase-
like 2 
(LOXL2)
Diamine oxidase 
(DAO)
Monoamine 
oxidase A 
(MAO-A)
Monoamine 
oxidase B 
(MAO-B)
Semicarbazide-
sensitive amine 
oxidase (SSAO)
PXS-S1A 6.8 < 5 < 5 5.1 < 4
PXS-S2A 8.3 < 5 < 5 < 5 < 5
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Figure 2: PXS compounds inhibit proliferation, migration and invasion in vitro. (A) Confluency (as % of control) of MDA-
MB-231 cells at 96 hours post seeding, in the presence of escalating doses of LOXL2 inhibitors PXS-S1A and PXS-S2A, showing dose 
dependent inhibition of proliferation. (n = 9 measurements over 3 independent experiments). (B) Absorption at 490nm (MTS Assay) of 
MDA-MB-231 cells in 1.8mg/mL 3D collagen I matrices at day 8 (measured as % of control), showing dose dependent inhibition of 
proliferation in response to LOXL2 inhibition (n = 9 measurements over 3 independent experiments) (C) Workflow and representative 
images for 2D scratch wound closure scoring. Using in house ImageJ scripts, first the wound edge is identified, before a mask is applied 
and the scratch area calculated. (D) LOXL2 inhibition leads to a dose-dependent decrease in scratch wound closure (plotted as % of control 
wound closure) (n = 12 wounds over 3 independent experiments) (E) Workflow and representative images for 3D spheroid invasion 
scoring. Using in house ImageJ scripts, a mask is generated of cells and the invaded areas calculated. (F) LOXL2 inhibition leads to a dose-
dependent decrease in 3D spheroid invasion (plotted as % of control spheroid invasion) (n = 12 spheroids over 3 independent experiments).
Figure 3: Stable LOXL2 knockdown decreases proliferation, migration and invasion in vitro. (A) qRT-PCR confirms 
transcriptional knockdown of the LOXL2 gene with 2 independent hairpins (shLOXL2 #1 and shLOXL2 #5) compared to control (shCon) 
(n = 3 independent experimental repeats). (B) Western blotting for LOXL2 protein confirms a reduction in expression levels in hairpins 
shLOXL2 #1 and shLOXL2 #5 compared to control (shCon). (C) shLOXL2 cells show reduced proliferation (MTS assay) in 2D on plastic 
compared to control shCon (n = 9 measurements over 3 independent experiments). (D) In 3D collagen I matrices, shLOXL2 cells show 
reduced proliferation (measured by cell count) over time (n = 9 measurements over 3 independent experiments). (E) 3D spheroid invasion 
assays; shLOXL2 cells show a significantly reduced invasive index (normalized to initial spheroid size [dotted line]) compared to control 
(shCon) (n = 9 spheroids from 3 independent experiments).
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LOXL2 inhibition decreases tumor angiogenesis 
to restrict growth
To determine how LOXL2 inhibition may be 
mediating the significant reduction in tumor volume, 
sections of orthotopic tumors were assessed for the 
marker of proliferation Ki67, and the apoptotic marker 
cleaved caspase-3. Despite being smaller, tumors treated 
with the PXS-S1A dual inhibitor showed no statistically 
significant alteration in Ki67 staining (Figure 5A and 5B). 
However PXS-S1A tumors did show a small but significant 
increase in the number of positive cleaved caspase-3 cells 
(Figure 5C and 5D). This is in contrast to the PXS-S2B 
LOXL2 specific inhibitor, which showed a small but 
statistically significant decrease in Ki67 staining with no 
significant changes in cleaved caspase-3 (Figure 5A–5D). 
This suggests that both generations of inhibitor are altering 
the balance between proliferation and apoptosis resulting 
in a reduced tumor burden. To confirm this, we also scored 
Ki67 and cleaved caspase-3 expression in our stable 
LOXL-2 knockdown lines when implanted orthotopically. 
Here we see a more significant effect whereby genetic 
silencing of LOXL2 in primary tumor cells leads to both a 
significant decrease in Ki67 expression (Figure 5E and 5F) 
and an increase in cleaved caspase-3 (Figure 5G and 5H). 
Given that we saw no change in the levels of other LOX 
family members upon stable shLOXL2 knockdown 
(Supplementary Figure 2A), we propose that in this 
instance, non-enzymatic functions of LOXL2 are likely 
contributing to the larger differences in proliferation and 
apoptosis compared to inhibitor-treated mice. However, we 
hypothesize that the effects of LOXL-2 inhibition, either 
genetically or pharmacologically, and enzymatic or non-
enzymatic, are not direct, but as a result of other changes to 
tumor physiology given the observed significant reduction 
in primary tumor volume in both models. 
 One of the biggest limiting factors of primary tumor 
growth is the availability of nutrients and oxygen as well 
as the removal of waste products. In order for tumors to 
expand in size to more than a few mm3 they depend on the 
ability to stimulate angiogenesis, known as the ‘angiogenic 
switch’ [17]. To that end, tumor angiogenesis has been 
classed as one of the major hallmarks of cancer [18, 19]. 
We tested whether the observed significant inhibition of 
primary tumor growth may be as a result of decreased tumor 
angiogenesis, which would act to restrict the rate of growth 
of the primary tumor. Immunohistochemical staining for 
the endothelial marker endomucin revealed a significant 
decrease in tumor angiogenesis and vessel count in both 
the dual LOX/LOXL2 inhibitor treated mice (PXS-S1A) 
and the LOXL2 specific inhibitor treated mice (PXS-S2B) 
(Figure 6A and 6B). Importantly, whereas in previous 
studies we noted a greater effect of dual inhibition, this was 
not the case for angiogenesis, and so we can conclude that 
the reduction in vessel density within the inhibitor treated 
tumors is a result of LOXL2 specific inhibition. Therefore 
our data show that early inhibition of LOXL2-mediated 
angiogenesis in developing primary breast cancer leads to 
the decrease in the growth of the primary tumor.
To further confirm that it was the specific inhibition 
of tumor-secreted LOXL2 responsible for driving tumor 
angiogenesis, and not stromal inhibition as a result of 
systemic treatment with the inhibitors, we also evaluated 
endomucin scoring in our two stable shLOX2 models. In 
these models we also see a similar significant reduction in 
intratumor vessel density, confirming that tumor-secreted 
LOXL2 promotes primary breast tumor angiogenesis and 
enhances primary tumor growth (Figure 6C and 6D).
LOXL2 inhibition decreases cancer-associated-
fibroblast activation
We have previously shown that high tumor 
LOXL2 levels are correlated with an increase in 
cancer associated fibroblasts (CAFs) within tumors 
[20]. The activation of stromal fibroblasts to CAFs 
Figure 4: Targeting LOXL2 in vivo delays tumor growth and reduces tumor burden. (A) Treatment of orthotopic MDA-MB-231 
human breast cancers in mice with PXS-S1A and (B) PXS-S2B significantly delays tumor growth and reduces tumor burden. (n = 2 
independent experiments; 3 mice) (C) Stable silencing of LOXL2 in MDA-MB-231 human breast cancer cells leads to delayed tumor 
growth and reduced tumor burden in orthotopic models (n = 2 independent experiments; 3 mice).
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Figure 5: LOXL2 inhibition effects on in vivo proliferation and apoptosis. (A) Immunohistochemistry for Ki67 shows limited 
effect of the PXS-S1A LOXL2 inhibitor, and a small but significant decrease in Ki67 score by treatment with the PXS-S2B LOXL2 
inhibitor in vivo (n = 2 independent experiments) (B) Representative images of Ki67 immunohistochemistry in tumors from control and 
PXS inhibitor treated mice. (C) Conversely, LOXL2 inhibition does not directly induce apoptosis in cells (PXS-S2A), whereas dual 
inhibition of LOX and LOXL2 (PXS-S1A) shows a significant increase in apoptosis. (n = 2 independent experiments). (D) Representative 
images of cleaved caspase-3 immunohistochemistry in tumors from control and PXS inhibitor treated mice. (E) Confirmation of findings 
in shLOXL2 tumors for Ki67 expression shows a significant decrease in tumors Ki67 score in vivo following LOXL2 silencing (n = 2 
independent experiments) (F) Representative images of Ki67 immunohistochemistry in tumors from shControl and shLOXL2 implanted 
mice. (G) Genetic silencing of LOXL2 leads to higher apoptosis in tumors as evaluated by cleaved-caspase-3 staining (n = 2 independent 
experiments). (H) Representative images of cleaved caspase-3 immunohistochemistry in tumors from shControl and shLOXL2 implanted 
mice. Scale = 150 µm.
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has been shown to be play a critical role in tumor 
progression and metastasis, and there are several efforts 
underway to target CAFs in solid tumors [21]. We 
hypothesized that in addition to inhibiting angiogenesis, 
LOXL2 inhibition may also decrease CAF activation. 
Using αSMA expression as a marker of activated 
fibroblasts, we confirmed that inhibition of LOXL2 
using both the PXS-S1A dual inhibitor and PXS-S2B 
LOXL2 specific inhibitor led to a significant decrease in 
the number of activated αSMA-positive fibroblasts in vivo 
(Figure 6E and 6F). Given the emerging importance of 
the tumor-promoting ability of αSMA–positive CAFs, 
which has been shown in breast, prostate, pancreatic, 
and skin cancer mouse models [22–24], the use of 
LOXL2 inhibitors to target both tumor angiogenesis and 
CAF activation offers a powerful approach for targeting 
developing primary breast tumors. Finally, to confirm this, 
we also evaluated αSMA positivity in shLOXL2 tumors 
and note a similar significant decrease in shLOXL2 
positivity compared to shControl. This further confirms 
our hypothesis that tumor-derived LOXL2 upregulates 
αSMA positivity within the tumors.
LOXL2 as a driver of metastasis
Finally, in addition to angiogenesis, CAF activation 
and primary tumor growth, we evaluated the effects 
of the two PXS inhibitors on metastatic dissemination 
in our human breast cancer model. To do this, primary 
tumors were implanted into the mammary fat pad as 
described above and treated with both the PXS-S1A dual 
inhibitor and PXS-S2B LOXL2 specific inhibitor once 
primary tumors became palpable (as described above). 
At experimental endpoints, lung and liver sections were 
taken, stained with Haematoxylin and Eosin (H&E), and 
scored for the presence of metastases. 
Treatment with the PXS-S1A dual LOX/LOXL2 
inhibitor led to a significant reduction in the number of 
metastases present within the lungs (Figure 7A and 7B) and 
liver (Figure 7C and 7D). Whilst this trend was repeated 
in the PXS-S2B treated mice, it was not significant, 
suggesting that LOXL2 enzymatic inhibition alone may 
not be fully sufficient to inhibit systemic metastases and 
that LOX plays a more dominant role in this process, in 
support of our previously published data [16, 25–27].
However, in contrast, our shLOXL2 stable 
knockdown cells showed a significant decrease in 
lung metastatic burden (Figure 7E and 7F). The 
stable knockdown of LOXL2 will affect all potential 
LOXL2 mediated interactions, both enzymatic and 
non-enzymatic protein-protein interactions. Since the 
PXS inhibitors can only block effects that are due to 
enzymatic activities, this data indicates that there may 
also be important non-enzymatic roles for LOXL2 in 
metastatic dissemination.
DISCUSSION
Here we present the first data to show that selective 
targeting of LOXL2 using small molecule inhibitors is 
effective against primary breast tumor burden. These 
effects are mediated through decreased angiogenesis and 
a subsequent reduction in CAF activation.
Previous results have suggested that LOXL2 
expression does not affect 2D cellular proliferation [7, 28]; 
however when embedded in matrix (3D proliferation), 
LOXL2 overexpression in breast epithelial cells did 
increase proliferation [28]. In the study presented here, 
we show that LOXL2 specific inhibition leads to a 
decrease in 2D proliferation, which also pertains to 3D 
proliferation. Furthermore, using the dual LOX/LOXL2 
inhibitor (PXS-S1A) and the LOXL2 specific inhibitor 
(PXS-S2A) we show that both LOX and LOXL2 play 
non-redundant roles in this setting. Our data further show 
that the effects of LOXL2 activity inhibition on breast 
cancer cell proliferation and ultimately tumor progression 
are manifested through an interaction with the surrounding 
microenvironment, and not necessarily a direct tumor cell 
response to LOXL2 enzymatic inhibition.
The pro-angiogenic effects of LOXL2 observed in 
our in vivo tumor studies have been further supported by 
previous research where LOXL2 has been demonstrated 
to be necessary for collagen IV assembly and organization 
in the endothelial basal lamina, a process critical to 
angiogenesis [29]. Indeed, another study using a LOXL2 
blocking antibody (AB0023) also showed efficacy against 
the angiogenic capabilities of endothelial cells, as well 
as a decrease in microvascular density in tumors [30]. 
Interestingly, in the latter study the authors showed that 
despite a reduction in tumor microvasculature, there 
were no effects on tumor growth; instead, the authors 
focused on how AB0023 treatment caused vasculature 
normalization, which in turn allowed for better delivery 
of therapeutics [30].
The effects on tumor growth observed in our 
study may also be in part due to the effect of LOXL2 
inhibition on reduced angiogenesis as well as CAF-
activation, something which was not reported in the 2013 
study, determining whether LOXL2 modulation of CAF 
activation and angiogenesis are mutually exclusive in 
this context is beyond the scope of this study. However 
recent reports would imply they are inexplicably 
intertwined in other solid tumours [31, 32]. Nonetheless, 
we have previously reported a role for LOXL2 in fibroblast 
activation through FAK signaling [20], and another study 
using the AB0023 anti-LOXL2 antibody has also shown 
that treated tumors exhibit significantly lower levels of 
activated fibroblasts (CAFs) [33]. These results support our 
findings here, whereby selective small molecule inhibition 
of LOXL2 results in a significantly lower numbers of 
αSMA positive CAFs within developing tumors.
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Figure 6: LOXL2 inhibition decreases tumor angiogenesis and CAF activation. (A) Inhibition of LOXL2 with PXS-S1A 
and PXS-S2B leads to a significant decrease in vessel density in primary breast tumors in vivo (measured by endomucin positive cells). 
(n = 2 independent experiments) (B) Representative images of endomucin immunohistochemistry in tumors from control and PXS inhibitor 
treated mice (C) The LOXL2 dependent reduction in vessel density was confirmed in our stable shLOXL2 lines which both show a 
significant decrease in endomucin positive vessels. (D) Representative images of endomucin immunohistochemistry in tumors from 
shControl and shLOXL2 implanted mice (E) Inhibition of LOXL2 using both the PXS-S1A and PXS-S2B compounds leads to a significant 
decrease in the number of activated αSMA-positive cells in primary tumors (F) Representative images of αSMA immunohistochemistry in 
tumors from control and PXS inhibitor treated mice. (G) Silencing of LOXL2 in MDA-MB-231 tumor cells leads to a significant decrease 
in the number of activated αSMA-positive cells within the primary tumors (H) Representative images of αSMA immunohistochemistry in 
tumors from shControl and shLOXL2 tumor bearing mice. Scale = 150 µm.
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Previous research from both our lab and other labs 
[7, 33] has identified an important role for LOXL2 in 
mediating breast cancer progression, and highlighted its 
therapeutic value. Here, we report the anti-tumor effects 
of the first selective LOXL2 small molecule inhibitors in 
models of human breast cancer. Our data strongly support the 
continued development of selective LOXL2 small molecule 
inhibitors for use in the treatment of human cancers.
Figure 7: Complete silencing of LOXL2 is required for reduction of metastatic burden. (A) Treatment with PXS-S1A 
showed a significant reduction in pulmonary metastatic burden, but not in PXS-S2B inhibitor treated mice (n = 2 independent experiments) 
(B) Representative H&E images of pulmonary metastatic burden in control and PXS inhibitor treated mice (C) Similarly, inhibition of 
LOXL2 with PXS-S1A showed a significant reduction in hepatic metastatic burden but this was not significant in the PXS-S2B treated 
mice (n = 2 independent experiments). (D) Representative H&E images of pulmonary hepatic burden in control and PXS inhibitor treated 
mice. (E) In contrast, genetic silencing of LOXL2 led to a significant reduction in pulmonary metastatic burden in shLOXL2 tumor bearing 
mice compared to shCon tumor bearing mice (F) Representative H&E images of lungs from shCon and shLOXL2 tumor implanted mice. 
Scale = 150 µm.
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MATERIALS AND METHODS
Animals and ethics statement
Female NCR nude mice were purchased from 
Charles River aged 8 weeks. All experiments were 
carried out in accordance with and under authorization 
and guidance from the Danish Inspectorate for Animal 
Experimentation.
Cell lines
MDA-MB-231 parental cells (ATCC) as well as 
shLOXL2 knockdown lines (detailed below) were cultured 
in standard Dulbecco’s Modified Eagle Media (DMEM) 
supplemented with 10% fetal bovine serum and 0.5% 
penicillin/streptomycin. All cell lines were routinely tested 
for mycoplasma and tested negative for murine pathogens 
by IMPACT testing (IDEXX Laboratories). 
Generation of stable shLOXL2 lines
For stable knock-down of LOXL2 (shLOXL2), 
HEK293T cells were grown to 40% confluency in T25 cm2 
flasks and transfected with 1.5 μg of shLOXL2 or shControl 
lentiviral construct together with 2 μg of packaging 
vector and 0.67 μg of envelope vector in antibiotic-free 
DMEM/10% fetal bovine serum, using Lipofectamine 
2000 according to manufacturer’s instructions. The 
shLOXL2 and shControl TRC Lentiviral Human constructs 
are available from Open Biosystems/GE Dharmacon and 
are targeted against lysyl oxidase homolog 2 [Homo 
sapiens] NP_002309.1. After overnight incubation, the 
media was changed to fresh DMEM/10% fetal bovine 
serum. 24 hours later, the lentivirus-containing media was 
collected and passed through a 45 μM filter. MDA-MB-231 
cells (described above) were cultured to 40% confluency 
in normal culture media without antibiotics and infected 
with viral supernatant in the presence of 4 μg/ml polybrene 
to increase infection efficacy. After 48 hours of infection, 
polyclonal populations of stably infected cells (MDA 
shLOXL2#1, shLOXL2#3, shLOXL2#5, shControl) were 
selected using 2 μg/ml puromycin.
Proliferation assays
2D proliferation on plastic of MDA-MB-231 breast 
cancer cells was assessed using both the Incucyte system 
(Essen BioScience), and CellTiter 96® Aqueous One 
Solution Cell Proliferation Assay (Promega), according to 
manufacturer’s instructions.
For the Incucyte system, cells were plated in 
triplicates of 2000 cells per well (96wp) in 100 μl of cell 
culture media. After overnight incubation, the media was 
changed to culture media containing either the desired 
dose of LOXL2 inhibitor, or mock treatment (DMSO); the 
plate was then incubated and imaged every two hours in 
the Incucyte system, over a period of 48 hours. 
For the 2D CellTiter 96 system, cells were plated at 
1000 cells per well (96wp) in 100 μl of cell culture media. 
After overnight incubation the drugs were added to the 
plates. For each time-point, 20 μl MTS reagent was added 
per well and the plate incubated in the dark for 2 hours 
at 37°C. Absorbance was then measured at 490 nm with 
an ELISA plate reader (Molecular Devices). All readings 
were normalized to day 1 readings.
3D proliferation in collagen I of the cells was 
assessed using either digestion of matrix followed by 
cell count, or the CellTiter 96 AQueous One Solution 
Cell Proliferation Assay (Promega), according to 
manufacturer’s instructions. For the CellTiter 96 system, 
cells were plated in triplicate in 96-well plates at 1000 cells 
per well in 50 μl of 1.8 mg/ml collagen I (BD Biosciences) 
mix. For the collagen I mix, rat tail collagen was mixed 
with 5 × DMEM, ddH2O and 23 μl NaOH per ml of 
collagen I used. The cell suspension was set in a 37°C 
incubator for an hour before 50 μl of culture medium, 
containing either LOXL2 inhibitor or with vehicle 
treatment, was added to each well. The culture medium 
was changed every 2 days. For each time-point, 20 μl MTS 
reagent was added per well and the plate incubated in the 
dark for 2 hours at 37°C. Absorbance was then measured at 
490 nm with an ELISA plate reader (Molecular Devices). 
All readings were normalized to day 1 readings. 
For the matrix digestion method, 5000 cells were 
plated in triplicates in 24-well plates in 1 ml of 1.8 mg/ml 
collagen I (BD Biosciences) mix. At each time point, 1mg/ml 
collagenase I was added to each well and incubated at 37°C 
for an hour, after which the number of cells in the digested 
suspension were counted using a cell counter. 
Hanging drop assays
The invasive capability of the cells was assessed 
using the hanging drop invasion assay. Spheres of cells 
were created by the hanging drop method described 
as followed: cells were trypsinized and resuspended 
at 400,000 cells/ml in culture media with 0.24% 
methylcellulose. The lid of a 10cm dish was inverted and 
20 μl drops of the cell suspension were aliquoted on the 
inside of the lid, after which the lid was carefully placed 
back on the dish, such that the drops of cell suspension 
were hanging off the lid due to gravity. After 24 hours 
of incubation at 37°C, spheres of cells aggregated at the 
bottom of the hanging drop. In a 48-well plate, 500 μl of 
1.8 mg/ml collagen I mix (described above) was added 
to each well and allowed to set for 5 minutes, before the 
spheres were carefully picked up using a 10 μl pipette and 
placed onto the half-set collagen mix. This was to ensure 
the spheres would not sink to the bottom of the plate 
and come into contact with the plastic surface. 4 spheres 
were placed into each well with ample distance between 
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each. The collagen was then allowed to set completely by 
incubating at 37°C for 1 hour, before the culture media 
(with LOXL2 inhibitor or vehicle treatment) was added 
and the spheres imaged immediately (T = 0) using a light 
microscope (Leica DM1L). The plates were then incubated 
at 37°C overnight, before another set of images were taken 
to assess the spread of invasive cells into the matrix.
Using ImageJ64 software a mask of the spread of 
cells was captured and areas were measured by generating 
a spheroid mask at all time points. An invasive index was 
calculated by calculating the ratiometric change in the 
mask area measured between timepoints.
2D scratch wound assay
2D migration and wound healing was carried out 
using a standard assay. Briefly, cells were plated in 96 
well plates and grown to 95% confluency. A single scratch 
wound was then created in each well using a 96-pin 
woundmaking tool (WoundMaker™ - Essen Bioscience). 
Following wounding cells were washed twice with pre-
warmed media and fresh media applied with either PXS 
inhibitors or vehicle control. Wounds were then imaged 
using an IncuCyte (Essen Bioscience). Images were then 
exported to ImageJ where an in house script was used 
to first define the wound margins and a mask applied to 
calculate the wound area.
Apoptosis assay
Apoptosis assays were carried out using the Cytotox 
Red apoptosis assay (Essen Biosciences) according to 
manufacturers instructions. 
Primary orthotopic tumor model
Adult female immunodeficient nude mice (NCR 
nude) aged between 7–8 weeks old and weighing between 
19–25 g were used for orthotopic studies. 1 × 107 cells 
were resuspended in 100 μl of sterile PBS and injected 
into 4th mammary fat pad on the right flank of the animal. 
Once the tumors were palpable (approximately 10 mm3 in 
measurement), drugs re-suspended in 2% Tween80/ddH2O 
(PXS-S1A at 2.5 mg/ml (dosed at 10 mg/kg); PXS-S2B at 
1.25 mg/ml (dosed at 5 mg/kg)) were administered daily 
through intraperitoneal injection. Tumor growth rate was 
measured every 3 days using calipers, and all mice were 
sacrificed when one of the tumors reached approximately 
1000 mm3 in size. The tumors, lungs and livers were 
excised and fixed in 4% PFA; these were then paraffin-
embedded, sectioned and stained with haematoxylin and 
eosin, or used for immunohistochemistry.
Immunohistochemistry
PFA-fixed tissues were embedded in paraffin 
according to standard histopathology approaches. 
Tissues were then sectioned at 4 microns. Sections were 
deparaffinized with xylene and rehydrated by immersion 
into decreasing concentrations of ethanol. Slides were 
then subjected to antigen retrieval by boiling in antigen 
retrieval buffer (Dako) for 20 minutes, and cooled to 
room temperature. Endogenous peroxidase activity was 
quenched through incubation in 3% hydrogen peroxide 
in methanol. Sections were washed 3× in PBS and 
blocked with 5% goat serum/2% BSA/PBS for 1 hour and 
incubated overnight with primary antibodies diluted in 
2% BSA/PBS at 4°C. Primary antibody dilutions were as 
follows [Endomucin Santa Cruz (sc-65495) IHC – 1:100; 
Activated caspase-3 Abcam (Ab2302) IHC – 1:100; 
Ki-67 Leica Microsystems (NCL-Ki67p) IHC – 1:100; 
αSMA Abcam 1A4 (ab7817) IHC 1:100]. Control slides 
with no primary antibodies added were incubated with 
just 2% BSA/PBS. After washing 3× with 0.1% BSA/
PBS, slides were incubated with respective anti-mouse 
or anti-rabbit biotinylated antibodies (Dako) for an hour. 
Slides were then washed 3× again with 0.1% BSA/PBS 
before visualization with either 3,3′-diaminobenzidine 
(DAB)(Dako) or Novared (VWR). Slides were then 
rinsed in H2O and counterstained with haematoxylin. 
After mounting and drying, slides were scanned using the 
Hammamatsu digital slide scanner, and quantification of 
positive staining was carried out using Image J64 analysis 
and in house scripts. 
qRT-PCR
Cells were lysed in Qiagen RLT buffer and 
homogenised with QIAshredder following manufacturer’s 
instructions. RNA was extracted from the lysates using 
the RNeasy Mini Kit and treated with DNaseI according 
to manufacturer’s instructions. Template cDNA was 
generated using Omniscript reverse transcriptase 
according to manufacturer’s instructions in the presence of 
RNaseOUT, and subsequently used for amplification. The 
PCR was performed using an Applied Biosystems 7900HT 
Fast Real-Time PCR system (Applied Biosystems, 
Carlsbad, CA). Gene expression for LOX, LOX1, 
LOXL2, LOXL3 and LOXL4 and GAPDH as control 
was measured using commercial TaqMan assays (Applied 
Biosystems) according to manufacturers specifications.
Western blotting
Immunoblotting for LOXL2 was as previously 
described [7, 20, 26, 28]. Immunoblotting for LOX, 
LOXL1, LOXL3 and LOXL4 was as previously 
described [26]. Primary LOXL2 antibody (Ab55470) 
was used at 1:1000 and b-actin (Abcam) at 1:10,000, 
with primary antibody incubation overnight at 4°C. The 
primary LOX antibody (synthesized by OpenBiosystems) 
targets a conserved peptide sequence from the active site 
of human and mouse LOX proteins and has been shown 
not to bind other LOX family members [25, 26, 34]. The 
LOX antibody was used at 1:500 dilution. The LOXL1 
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antibody (Abcam (AB87748)) was used at 1:100 dilution. 
The LOXL3 antibody (Abcam (AB171315)) was used 
at 1:200 dilution. The LOXL4 antibody (Santa Cruz 
(sc-66952)) was used at 1:100 dilution. Vinculin (Sigma) 
was used at 1:500 dilution. Species-specific HRP 
secondary antibodies (Dako) were used at 1:30,000 and 
incubated for 1 h at room temperature, and visualization 
performed using ECL Plus (Amersham, GE Healthcare).
Activity/inhibition assays 
The standard amplex red assay has been used as 
previously described [14] using putrescine as a substrate 
and native ´fibroblast derived LOX, which was prepared 
by collecting the supernatant of IMR90 cells, followed by 
a size filtration > 10 kDa for concentration and < 50 kDa 
to separate from LOXL2, or recombinant LOXL2 as 
enzyme (R&D Systems).
Data analysis
Data was analyzed using the Student t test unless 
otherwise stated, and considered statistically significant 
when the P value was less than 0.05. Graphs represent 
the mean and standard deviation. Details for replicates 
are given in Figure legends. Statistical significance 
representations are as follows: *P < 0.05, **P < 0.01, 
***P < 0.001. Statistical analyses were performed using 
Prism statistical package version 6.
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